Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...

New year, new you! Getting healthy is a popular resolution and to meet goals, some people may turn to weight-loss drugs for ...

The series tackles the ‘GLP-1 revolution,’ created to educate consumers about the medication’s potential uses and side ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Eli Lilly & Co. (LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026. CEO Dave Ricks ...

Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...